Another victory for Jab.
GLP-1 drugs such as OzemPIC and Wegovy have been linked to a range of benefits that exceed the management of diabetes and weight loss, from the low risk of dementia to addiction treatment.
I have now found a new research from Israel that it can significantly reduce the risk of obese-related cancer-which is more effective than weight loss surgery.
The study was published in Lancet's Eclinicalmedicine, she looked at thousands of obese and diabetes who were on GLP-1 drugs including Liraglutide (Saxenda), EXENATIDE (Byetta) and Dulaglutide (Truelicity).
Included (OzemPIC) and Tirzepatide (Zepbound) were not included in the study.
Obesity is associated with 13 cancers, and weight loss can reduce this risk. But researchers found that the effect of these drugs on the development of cancer is greater than just the help of weight loss.
This is because they compared drug users to lose weight with those who underwent obesity treatment for weight loss-and their results decided that the drugs were “41 % more effective in preventing obesity cancer,” according to Dr. Yale Wolf Sagy than health services in Clalit in Talal, Israel, author of the study.
She said: “We do not fully understand how the GLP-1 works, but this study adds to the increasing evidence that it turns out that weight loss alone cannot be completely explained, anti-cancer, and many other benefits provided by these medications.”
“The preventive effects of the GLP-1ras against obesity-related cancers are likely to arise from multiple mechanisms, including reducing inflammation,” added the preventive author of the GLP-1ras against obesity cancer, which is likely to arise from multiple mechanisms, including reducing inflammation, “added the co-author Dr. Dar Decker from Hasharon Hospital, Rabin Medical Center, Beita Tikva, Israel.
The new study can mean pioneering changes in cancer prevention, according to Professor Mark Luller, a cancer research expert at Queens Belfast University who did not participate in the study.
“We already know that obesity surgery reduces the risk of obesity-related cancer by about a third. This data indicates that the targeted GLP-1 may reduce this risk by approximately 50 %-a approach that would be a shift in preventing obesity-related cancer.”
“This work can bode an entirely new era of preventive cancer.”
Doctors previously identified GLP-1 as a useful weight loss tool to prevent obesity cancer, although he believed that the risk reduced so far due to weight changes.
Obesity is associated with 13 types of cancer, including breasts, prostate, uterus, pancreas, colon, kidneys and liver.
A study published last year found that people with GLP-1 drugs reduced the risk of 10 obesity-related cancers.
“These drugs promote great weight loss, which reduces obesity -related cancer risk,” said the main author, Lindsey Wang, a medical and research student at Kis Western Reserve University in Cleveland. “It also enhances insulin sensitivity and low insulin levels, which reduces cancer cell growth signals.”
